Clinical Nutrition
Volume 29, Issue 5 , Pages 592-599, October 2010

n3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: A double-blind, cross-over study☆☆

Department of Nutritional Physiology, Institute of Nutrition, Friedrich Schiller University, Dornburger Str. 24, D-07743 Jena, Germany

Received 17 November 2009; accepted 20 February 2010. published online 02 March 2010.

Summary 

Background: & aims

The effects of n3 LC-PUFA-supplemented dairy products on cardiovascular risk factors in mildly hypertriacylglycerolemic patients (TAG: ≥1.5mmol/L) were determined.

Methods

Fifty-one patients (25 f, 26 m) were included in the double-blind, placebo-controlled cross-over study and were randomly divided into two groups. Both groups received intervention (3g n3 LC-PUFA/d) and control dairy products consecutively for fifteen weeks with a ten-week wash-out phase between the two treatments. Blood samples and 24-h urine were obtained at the beginning and at the end of each period.

The blood lipids were determined by enzymatic methods and using the autoanalyser Synchron LX systems (Beckman Coulter). 7,8-Dihydro-8-oxo-2′-deoxyguanosine and fatty acids were analysed with HPLC and GC.

Results

Generally, the consumption of the intervention products resulted in a significant improvement of cardiovascular risk factors, e.g., n3 FA index, AA/EPA ratio, total cholesterol, and TAG. The TAG and LDL/HDL ratio were lower at the end of the intervention period in comparison with the control period, whereas HDL cholesterol was higher at the end of the intervention period. Further, n3 LC-PUFA-enriched products did not cause additional oxidative DNA damage as shown by the 7,8-dihydro-8-oxo-2′-deoxyguanosine excretion.

Conclusions

The consumption of n3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors.

Keywords: Dairy products, n3 LC-PUFA, Serum lipids, DNA damage

Abbreviations: CHD, coronary heart diseases, SFA, saturated fatty acids, EPA, eicosapentaenoic acid (C20:5, n3), DHA, docosahexaenoic acid (C22:6, n3), AA, arachidonic acid (C20:4, n6), TXA2, thromboxane A2, COX, cyclooxygenase, TAG, triacylglycerides, CLA, conjugated linoleic acids, FFP, Food Frequency Protocol, TC, total cholesterol, CRP, c-reactive protein, 8-oxodG, 7,8-dihydro-8-oxo-2′-deoxyguanosine, Cr, creatinine, EM, erythrocyte membranes, PL, plasma lipids, FAME, fatty acid methyl esters, DPA, docosapentaenoic acid (C22:5, n6), LA, linoleic acid (C18:2, n6), ALA, α-linolenic acid (C18:3, n3), RDA, US Recommended Dietary Allowance, WDP, Western Dietary Pattern

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conference presentation: 6th Euro Fed Lipid Congress, Athen, Greece, 2008; ENA Congress, Wiesbaden, Germany, 2009; Symposium “Functional Foods”, Kiel, Germany, 2009; 6th NIZO Dairy Conference, Papendal, The Netherlands, 2009.

☆☆ Clinical Trails: Registration number – NCT00639041.

PII: S0261-5614(10)00038-5

doi:10.1016/j.clnu.2010.02.008

Clinical Nutrition
Volume 29, Issue 5 , Pages 592-599, October 2010